Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 3, 2012, Pages 725-734

  Liu, Yingmei ^a   Webb, Heather K ^c   Fukushima, Hisayo ^a   Micheli, Janine ^a   Markova, Svetlana ^a   Olson, Jean L ^b   Kroetz, Deanna L ^a  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Arête Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ADAMANTAN 1 YL 3 (1 METHYLSULFONYL PIPERADIN 4 YL UREA); AR 9273; CISPLATIN; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; IMMUNOREACTIVITY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

8,11,14-EICOSATRIENOIC ACID; ACUTE KIDNEY INJURY; ADAMANTANE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; CISPLATIN; CREATININE; ENZYME INHIBITORS; EPOXIDE HYDROLASES; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861551890     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.191247     Document Type: Article

References (49)

1. Burdon KP, Lehtinen AB, Langefeld CD, Carr JJ, Rich SS, Freedman BI, Herrington D, and Bowden DW (2008) Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study. Diab Vasc Dis Res 5:128-134. (Pubitemid 351839285)
2. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, and Weiss RH (2002) Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A 99:2222-2227. (Pubitemid 34169042)
3. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, et al. (2001) Interleukin-10 inhibits ischemic and cisplatininduced acute renal injury. Kidney Int 60:2118-2128. (Pubitemid 33070455)
4. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, et al. (2007) Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1β, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322:8-15. (Pubitemid 46956357)
5. Fava C, Montagnana M, Danese E, Almgren P, Hedblad B, Engström G, Berglund G, Minuz P, and Melander O (2010) Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes. Pharmacogenet Genomics 20:94-103.
6. Fife KL, Liu Y, Schmelzer KR, Tsai HJ, Kim IH, Morisseau C, Hammock BD, and Kroetz DL (2008) Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation. J Pharmacol Exp Ther 327:707-715.
7. Fleming I, Michaelis UR, Bredenkötter D, Fisslthaler B, Dehghani F, Brandes RP, and Busse R (2001) Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88:44-51. (Pubitemid 32064081)
8. Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, and Wong ND (2004) Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 109:335-339. (Pubitemid 38133900)
9. Francescato HD, Costa RS, Scavone C, and Coimbra TM (2007) Parthenolide reduces cisplatin-induced renal damage. Toxicology 230:64-75. (Pubitemid 46084872)
10. Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690-694. (Pubitemid 34165207)
11. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, and Hammock BD (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46:975-981.
12. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
13. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, and Leder P (1998) The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8:297-303. (Pubitemid 28188890)
14. Kelly KJ, Meehan SM, Colvin RB, Williams WW, and Bonventre JV (1999) Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney Int 56:922-931. (Pubitemid 29411719)
15. Kroetz DL and Zeldin DC (2002) Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol 13:273-283. (Pubitemid 34592284)
16. Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, and Zeldin DC (2006a) Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 15:1640-1649. (Pubitemid 43904830)
17. Lee CR, Pretorius M, Schuck RN, Burch LH, Bartlett J, Williams SM, Zeldin DC, and Brown NJ (2011) Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans. Hypertension 57:116-122.
18. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, and Park SK (2006b) Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 21:2096-2105. (Pubitemid 44295034)
19. Li S, Gokden N, Okusa MD, Bhatt R, and Portilla D (2005) Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 289:F469-F480. (Pubitemid 41003677)
20. Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, Chiamvimonvat N, and Hammock BD (2010) Inhibition of soluble epoxide hydrolase enhances the antiinflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 79:880-887.
21. Luo P, Chang HH, Zhou Y, Zhang S, Hwang SH, Morisseau C, Wang CY, Inscho EW, Hammock BD, and Wang MH (2010) Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther 334:430-438.
22. Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang H, Gill R, Morisseau C, Newman JW, and Hammock BD (2007) Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 282:2891-2898. (Pubitemid 47084334)
23. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, Brands MW, Hammock BD, and Imig JD (2009) Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 297:F740-F748.
24. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gösele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, et al. (2008) Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 40:529-537. (Pubitemid 351601216)
25. Newman JW, Watanabe T, and Hammock BD (2002) The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res 43:1563-1578.
26. Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, and Kroetz DL (2007) Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor α. Drug Metab Dispos 35:1126-1134. (Pubitemid 46956433)
27. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276-1279. (Pubitemid 29398616)
28. Pabla N and Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994-1007. (Pubitemid 351543900)
29. Parrish AR, Chen G, Burghardt RC, Watanabe T, Morisseau C, and Hammock BD (2009) Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol Toxicol 25:217-225.
30. Ramesh G and Reeves WB (2002) TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835-842.
31. Ramesh G and Reeves WB (2003) TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285:F610-F618. (Pubitemid 37140245)
32. Ramesh G and Reeves WB (2004) Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-α. Kidney Int 65:490-499.
33. Santee SM and Owen-Schaub LB (1996) Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. J Biol Chem 271:21151-21159. (Pubitemid 26292967)
34. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, and Hammock BD (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 102:9772-9777. (Pubitemid 40993644)
35. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, et al. (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99:442-450. (Pubitemid 44253701)
36. Simpkins AN, Rudic RD, Roy S, Tsai HJ, Hammock BD, and Imig JD (2010) Soluble epoxide hydrolase inhibition modulates vascular remodeling. Am J Physiol Heart Circ Physiol 298:H795-H806.
37. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, and Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275:40504-40510. (Pubitemid 32064687)
38. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, and Hammock BD (2005) Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A 102:2186-2191. (Pubitemid 40262033)
39. Spector AA, Fang X, Snyder GD, and Weintraub NL (2004) Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43:55-90. (Pubitemid 37433867)
40. Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, et al. (2003) Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 63:72-82. (Pubitemid 35463908)
41. Wang YX, Ulu A, Zhang LN, and Hammock B (2010) Soluble epoxide hydrolase in atherosclerosis. Curr Atheroscl Rep 12:174-183.
42. Yang S, Lin L, Chen JX, Lee CR, Seubert JM, Wang Y, Wang H, Chao ZR, Tao DD, Gong JP, et al. (2007a) Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-α via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol 293:H142-H151. (Pubitemid 47105069)
43. Yang W, Holmes BB, Gopal VR, Kishore RV, Sangras B, Yi XY, Falck JR, and Campbell WB (2007b) Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. J Pharmacol Exp Ther 321:1023-1031. (Pubitemid 46762683)
44. Yao J, Mackman N, Edgington TS, and Fan ST (1997) Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-κB transcription factors. J Biol Chem 272:17795-17801. (Pubitemid 27311220)
45. Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, and Kroetz DL (2000a) Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol 57:1011-1020. (Pubitemid 30253386)
46. Yu Z, Ng VY, Su P, Engler MM, Engler MB, Huang Y, Lin E, and Kroetz DL (2006) Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary γ-linolenic acid. J Pharmacol Exp Ther 317:732-738.
47. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, et al. (2000b) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87:992-998.
48. Zhang B, Ramesh G, Norbury CC, and Reeves WB (2007) Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells. Kidney Int 72:37-44. (Pubitemid 47014442)
49. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, and Imig JD (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 15: 1244-1253. (Pubitemid 38526005)